Series “A” round of CHF 25 million
Gezondheidszorg & farmacie
IT, online & e-commerce
The company is the first company to act with digital optical information on the outcome of a major disease, breast cancer. It shortens significantly and improves drastically the breast cancer treatment process by giving oncologists, with its proprietary non-invasive optical molecular digital data technology, critical in vivo tissue’s pathophysiological activity information to immediately select the most efficacious and individualized cancer treatment for a given patient. It thus avoids the successive invasive trials and potential inefficacy of 2 or 3 treatments over 2-3 months for each. It permits physicians to remotely monitor the progress of their treatments. In addition, it may in the future replace mammography with a much earlier, non-invasive and accurate diagnosis of breast cancer for a wider range of women, from teenage to senior years, in private physician offices or at home.
Reason to sell
The entrepreneur wants to attract a strategic partner.
The company is interesting for strategic buyers/investors. The company is interesting as well for entreprenerial MBI candidates who have knowledge of the sector.
The offered stake is to be discussed.
To be discussed.
The asking price is € 25.000.000.